Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Jim Silverman

Contributor

Email This Author

Jim Silverman is the managing member of RRC Bio Fund LP, a Boston-based hedge fund focused on small-cap biotech. RRC Bio was launched in 2007. Silverman also founded Risk/Reward Capital Management in 1997, a registered investment advisory. He lives in Cambridge, Mass., and received a BBA in finance from The George Washington University.

Jim Silverman
By This Author:
« Back
Page 1 of 1
Next »
Article

Cell Therapeutics: Addicted to Reverse Stock Splits

By Jim Silverman

Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.

Related Topics: Biotech | Drugs | Health Care

10:00AM 04/18/13

Article

Programmed Insider Buying? Yes, at Insmed and United Therapeutics

By Jim Silverman

Instead of selling stock whenever the wind blows, biotech execs should be buying.

Related Topics: Biotech | Drugs | Health Care

08:00AM 01/24/13

Article

Genta: 1998-2012

By Jim Silverman

The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.

Related Topics: Biotech | Drugs | Health Care | Business News

07:00AM 10/25/12

Article

Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data

By Jim Silverman

How best to invest in the next important clinical trial catalyst facing Celgene.

Related Topics: Biotech | Drugs | Health Care

08:07AM 09/25/12

« Back
Page 1 of 1
Next »

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 15,303.10 8.60 0.06%
NASDAQ 3,459.14 -0.28 -0.01%
S&P 500 1,649.60 -0.91 -0.06%
US 10 Yr 2.011% -0.012

Brokerage Partners
Advertising Partners

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Manage Newsletters

Top Rated Stocks Top Rated Funds Top Rated ETFs